Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
Lijing Wang College of Life Sciences and Technology, China Pharmaceutical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence: Lijing Wang, College of Life Science and Technology, China Pharmaceutical University, 639 Longmian Avenue, Jiangning District, Nanjing, Jiangsu,...
Saved in:
Main Author: | Wang L (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2022-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
by: Karen Schneck, et al.
Published: (2024) -
Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review
by: Bartłomiej Stachyra, et al.
Published: (2023) -
INITIATING PATIENTS ON GLP-1/COMBINED GLP-1 AND GIP AGONISTS: A QUALITY IMPROVEMENT PROJECT
by: Shreya Srivastava, MD, MPH
Published: (2024) -
Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024) -
Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice
by: Seun Akindehin, et al.
Published: (2024)